Indications
Orladeyo is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older.
Composition
- Active substance
- berotralstat dihydrochloride
- International name (INN)
- berotralstat
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Orladeyo
- Active substance
- berotralstat dihydrochloride
- ATC code
- B06AC
- Therapeutic area
- Angioedemas, Hereditary
- Marketing authorisation holder
- BioCryst Ireland Limited